Previous 10 | Next 10 |
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these...
2024-01-20 09:00:00 ET Summary Longleaf Partners Funds is a suite of mutual funds and UCITS funds that Southeastern Asset Management, the investment advisor to the Longleaf Partners Funds, created in 1987 as a way for Southeastern employees to invest alongside their clients. Longl...
2024-01-11 12:14:06 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced that Norman Schwartz, President and CEO, and Andrew Last, Executive Vice President and COO, will host one-on-one meetings with investors during the 42nd Ann...
2023-11-25 05:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-15 10:41:34 ET More on JFrog, Louisiana-Pacific, etc. Spectrum Brands Holdings: A Messy But Appealing Prospect Heading Into Q4 Earnings JFrog: A High-Quality Company With Little Margin of Safety Raymond James cuts Masimo to market perform, cites lack of visib...
2023-10-26 20:04:05 ET Bio-Rad Laboratories, Inc. (BIO) Q3 2023 Results Conference Call October 26, 2023 05:00 PM ET Company Participants Edward Chung - Head, IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andy Last - EVP and COO Simon May - President...
2023-10-26 17:07:37 ET More on Bio-Rad Labs Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance Bio-Rad: A Cash Flow Returns On Investments Analysis Bio-Rad Laboratories, Inc. (BIO) Q2 2023 Earnings Call Transcript Bio-Rad Labs Q...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent comp...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
News, Short Squeeze, Breakout and More Instantly...
Bio-Rad Laboratories Inc. Class A Company Name:
BIO Stock Symbol:
NYSE Market:
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferi...
2024-05-09 12:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...